Nice not sure whether to approve blood clot drug
March 13, 2012
Nice has been unable to reach a decision on Bayer's DVT therapy rivaroxaban.
The National Institute for Health and Clinical Excellence (Nice) has asked pharmaceutical firm Bayer to provide more information on a drug called rivaroxaban.
Nice is currently appraising the drug as a potential treatment for deep vein thrombosis (DVT), as well as the prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT.
However, the healthcare guidance body said today (March 13th) that it needs further evidence on the drug's clinical and cost-effectiveness before reaching a decision.
This means that unless it can be convinced that the drug's health benefits outweigh the financial costs, rivaroxaban may only be available to patients with private medical insurance or the means to pay.
Spokesman Meindert Boysen explained: "The committee was unable to make a decision on the data presented by the manufacturer because it felt that the data failed to demonstrate the drug's clinical and cost-effectiveness in the context of UK clinical practice."
He confirmed that Nice has requested further information from Bayer before drawing up its next draft guidance.
The Scottish Medicines Consortium recently accepted rivaroxaban for use within NHS Scotland, although it noted that the lack of data on the drug's use for more than 12 months means "the cost-effectiveness of indefinite treatment has not been demonstrated".